ARTICLE | Company News

NICE issues draft guidances on HCV treatments

July 30, 2015 1:08 AM UTC

The U.K.'s NICE published three draft guidances recommending Daklinza daclatasvir from Bristol-Myers Squibb Co. (NYSE:BMY), Viekirax ombitasvir/paritaprevir and Exviera dasabuvir from AbbVie Inc. (NYSE:ABBV), and Harvoni ledipasvir/ sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) for certain populations of HCV patients.

NICE recommended a 12-week course of Daklinza plus Gilead's Sovaldi sofosbuvir for non-cirrhotic HCV genotype 1 and 4 patients with significant fibrosis who have been previously treated or who are ineligible or intolerant of interferon. The draft guidance did not recommend Daklinza plus Sovaldi for untreated genotype 1 or 4 patients, nor for those with genotype 3. ...